Showing results (541-550 of 622) with videos related to

Sort By:
Pageof 63
BMC Genomics|November 1, 2008
Towards the understanding of the cocoa transcriptome: Production and analysis of an exhaustive dataset of ESTs of Theobroma cacao L. generated from various tissues and under various conditionsXavier Argout, Olivier Fouet, Patrick Wincker, et al.
The Oncologist|October 14, 2022
Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL TrialSerena Di Cosimo, José Manuel Pérez-García, Meritxell Bellet, et al.
Circulation Research|March 18, 2024
Extracellular Kir2.1<sup>C122Y</sup> Mutant Upsets Kir2.1-PIP<sub>2</sub> Bonds and Is Arrhythmogenic in Andersen-Tawil SyndromeFrancisco M Cruz, Álvaro Macías, Ana I Moreno-Manuel, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 8, 2024
Clinicopathological and molecular predictors of [<sup>18</sup>F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trialAntonio Llombart-Cussac, Aleix Prat, José Manuel Pérez-García, et al.
Critical Care (London, England)|August 22, 2025
Detecting heart failure in severe asthma patients using speckle tracking echocardiographyJavier Hidalgo-Martín, María Del Carmen Ruiz-Iniesta, María Dolores Pola-Gallego-de-Guzmán, et al.
Biorxiv : the Preprint Server for Biology|June 19, 2023
Extracellular cysteine disulfide bond break at Cys122 disrupts PIP<sub>2</sub>-dependent Kir2.1 channel function and leads to arrhythmias in Andersen-Tawil SyndromeFrancisco M Cruz, Álvaro Macías, Ana I Moreno-Manuel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2025
Camizestrant in combination with three globally approved CDK4/6 inhibitors in women with ER+, HER2- advanced breast cancer: Results from SERENA-1Richard D Baird, Begoña Bermejo de Las Heras, Manuel Ruiz-Borrego, et al.
The Oncologist|April 25, 2015
Defining breast cancer intrinsic subtypes by quantitative receptor expressionMaggie C U Cheang, Miguel Martin, Torsten O Nielsen, et al.
Medrxiv : the Preprint Server for Health Sciences|December 23, 2024
Kir2.1 mutations differentially increase the risk of flecainide proarrhythmia in Andersen Tawil SyndromeFrancisco M Cruz, Ana I Moreno-Manuel, Patricia Sánchez Pérez, et al.
Nature Medicine|June 4, 2025
Atezolizumab plus paclitaxel and bevacizumab as first-line treatment of advanced triple-negative breast cancer: the ATRACTIB phase 2 trialMaría Gion, Isabel Blancas, Patricia Cortez-Castedo, et al.
Pageof 63